MedWatch

Financial analyst raises share price target for Lundbeck due to Rexulti potential

Lundbeck shares may gain added value, if the firm successfully expands the number of diseases that can be treated with its Rexulti treatment, according to financial services group.

Photo: Jens Dresling

The market is currently underestimating the underlying potential of a couple of Lundbeck's drugs, according to Norwegian financial services group DNB, which raises its share price target to DKK 305 (USD 49.3) from DKK 280 and reiterates its recommendation to buy.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs